Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis

Journal of Cellular Physiology

Volumn 233, Issue 4, 2018, Pages 3352-3374

  Zhang, Shu Hua ^a   Liu, Gui Feng ^a   Li, Xue Feng ^a   Liu, Lin ^a   Yu, Shao Nan ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

advanced metastatic pancreatic cancer; Bayesian network model; chemotherapy regimens; efficacy; network meta analysis; randomized controlled trials

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; EXATECAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ANALOGS AND DERIVATIVES; HUMAN; META ANALYSIS; NETWORK META-ANALYSIS; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IRINOTECAN; NETWORK META-ANALYSIS; OXALIPLATIN; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85038947168     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.26183     Document Type: Article

References (54)

1. Abou-Alfa, G. K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N. S., … O'Reilly, E. M. (2006). Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 4441–4447.
2. Assaf, E., Verlinde-Carvalho, M., Delbaldo, C., Grenier, J., Sellam, Z., Pouessel, D., … Culine, S. (2011). 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology, 80, 301–306.
3. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., … Von Hoff, D. D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 15, 2403–2413.
4. Chaimani, A., Higgins, J. P., Mavridis, D., Spyridonos, P., & Salanti, G. (2013). Graphical tools for network meta-analysis in STATA. PLoS ONE, 8, e76654.
5. Chao, Y., Wu, C. Y., Wang, J. P., Lee, R. C., Lee, W. P., & Li, C. P. (2013). A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 72, 637–642.
6. Chen, L. X., Li, Y. L., Ning, G. Z., Li, Y., Wu, Q. L., Guo, J. X., … Feng, S. Q. (2015). Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: A network meta-analysis and systematic review. PLoS ONE, 10, e0123153.
7. Chung, J. H., & Lee, S. W. (2013). Assessing the quality of randomized controlled urological trials conducted by korean medical institutions. Korean Journal of Urology, 54, 289–296.
8. Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., … Lopez, M. (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer, 94, 902–910.
9. Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Carteni, G., Massidda, B., … Gruppo Oncologico Italiano di Ricerca C. (2010). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 1645–1651.
10. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., … Intergroup P. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364, 1817–1825.
11. Conroy, T., Paillot, B., Francois, E., Bugat, R., Jacob, J. H., Stein, U., … Deplanque, G. (2005). Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 1228–1236.
12. Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., … Neoptolemos, J. P. (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 5513–5518.
13. Deng, T., Yuan, Y., Zhang, C., Zhang, C., Yao, W., Wang, C., … Ba, Y. (2016). Identification of circulating miR-25 as a potential biomarker for pancreatic cancer diagnosis. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 39, 1716–1722.
14. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177–188.
15. Di Costanzo, F., Carlini, P., Doni, L., Massidda, B., Mattioli, R., Iop, A., … Gasperoni, S. (2005). Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer, 93, 185–189.
16. Dimcevski, G., Kotopoulis, S., Bjanes, T., Hoem, D., Schjott, J., Gjertsen, B. T., … Gilja, O. H. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release: Official Journal of the Controlled Release Society, 243, 172–181.
17. Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., … Von Hoff, D. D. (2015). Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. Journal of the National Cancer Institute, 107.
18. Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., … Conroy, T. (2013). Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 23–29.
19. Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., … Wilkowski, R. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 3946–3952.
20. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schuller, J., … Swiss Group for Clinical Cancer R, Central European Cooperative Oncology G. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advance'd pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 2212–2217.
21. Hess, V., Pratsch, S., Potthast, S., Lee, L., Winterhalder, R., Widmer, L., … Herrmann, R. (2010). Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): A phase I/II trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 21, 2390–2395.
22. Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., … Cochrane Statistical Methods G. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, d5928.
23. Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., … Moher, D. (2015). The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Annals of Internal Medicine, 162, 777–784.
24. Inal, A., Kos, F. T., Algin, E., Yildiz, R., Dikiltas, M., Unek, I. T., … Isikdogan, A. (2012). Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A retrospective analysis of multicenter study. Neoplasma, 59, 297–301.
25. Kasuga, A., Okano, N., Naruge, D., Kitamura, H., Takasu, A., Nagashima, F., & Furuse, J. (2015). Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: Inflammation-based prognostic score predicts survival. Cancer Chemotherapy and Pharmacology, 75, 457–464.
26. Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004). Pancreatic cancer. Lancet, 363, 1049–1057.
27. Li, X., Wang, K., Zheng, L., & Meng, Z. (2016). Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. American Journal of Cancer Research, 6, 84–90.
28. Louvet, C., Andre, T., Lledo, G., Hammel, P., Bleiberg, H., Bouleuc, C., … de Gramont, A. (2002). Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20, 1512–1518.
29. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., Andre, T., … Giscad. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 3509–3516.
30. Luo, Y., Gao, S., Hao, Z., Yang, Y., Xie, S., Li, D., … Zhou, J. (2016). Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer. Oncotarget, 7, 75155–75164.
31. Maeda, A., Boku, N., Fukutomi, A., Kondo, S., Kinoshita, T., Nagino, M., & Uesaka, K. (2008). Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Japanese Journal of Clinical Oncology, 38, 227–229.
32. Nakai, Y., Isayama, H., Sasaki, T., Sasahira, N., Tsujino, T., Toda, N., … Koike, K. (2012). A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. British Journal of Cancer, 106, 1934–1939.
33. Nakamura, K., Yamaguchi, T., Ishihara, T., Sudo, K., Kato, H., & Saisho, H. (2006). Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. British Journal of Cancer, 94, 1575–1579.
34. Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., … Kindler, H. L. (2005). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 16, 1639–1645.
35. Ozaka, M., Matsumura, Y., Ishii, H., Omuro, Y., Itoi, T., Mouri, H., … Nakajima, T. (2012). Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemotherapy and Pharmacology, 69, 1197–1204.
36. Peng, P., Ou, X., Liao, H., Liu, Y., Wang, S., Cheng, Z., & Lin, Z. (2016). Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 8, 153–159.
37. Peron, J., Roy, P., Conroy, T., Desseigne, F., Ychou, M., Gourgou-Bourgade, S., … Buyse, M. (2016). An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 7, 82953–82960.
38. Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., … Miller, L. L. (2004). Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22, 3776–3783.
39. Rombouts, S. J., Mungroop, T. H., Heilmann, M. N., van Laarhoven, H. W., Busch, O. R., Molenaar, I. Q., … Wilmink, J. W. (2016). FOLFIRINOX in locally advanced and metastatic pancreatic cancer: A single centre cohort study. Journal of Cancer, 7, 1861–1866.
40. Rothenberg, M. L., Moore, M. J., Cripps, M. C., Andersen, J. S., Portenoy, R. K., Burris, H. A., 3rd, … Von Hoff, D. D. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 7, 347–353.
41. Salanti, G., Ades, A. E., & Ioannidis, J. P. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. Journal of Clinical Epidemiology, 64, 163–171.
42. Scheithauer, W., Schull, B., Ulrich-Pur, H., Schmid, K., Raderer, M., Haider, K., … Kornek, G. V. (2003). Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 14, 97–104.
43. Schilsky, R. L., Bertucci, D., Vogelzang, N. J., Kindler, H. L., & Ratain, M. J. (2002). Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20, 582–587.
44. Stathopoulos, G. P., Syrigos, K., Aravantinos, G., Polyzos, A., Papakotoulas, P., Fountzilas, G., … Georgoulias, V. (2006). A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer, 95, 587–592.
45. Stathopoulos, G. P., Syrigos, K., Polyzos, A., Fountzilas, G., Rigatos, S. K., Ziras, N., … Georgoulias, V. (2004). Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 15, 224–229.
46. Sudo, K., Ishihara, T., Hirata, N., Ozawa, F., Ohshima, T., Azemoto, R., … Yamaguchi, T. (2014). Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 73, 389–396.
47. Sudo, K., Yamaguchi, T., Ishihara, T., Nakamura, K., Hara, T., Denda, T., … Yokosuka, O. (2011). Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics, 80, 119–125.
48. Sudo, K., Yamaguchi, T., Nakamura, K., Denda, T., Hara, T., Ishihara, T., & Yokosuka, O. (2011). Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 67, 249–254.
49. Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., 3rd, & Casper, E. S. … National Comprehensive Cancer N. (2012). Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 10, 703–713.
50. Tsukuda, M., Kida, A., Fujii, M., Kono, N., Yoshihara, T., Hasegawa, Y., … Neck, C. (2005). Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. British Journal of Cancer, 93, 884–889.
51. Tu, Y. K., Needleman, I., Chambrone, L., Lu, H. K., & Faggion, C. M., Jr. (2012). A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. Journal of Clinical Periodontology, 39, 303–314.
52. Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., … Tanaka, M. (2013). Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 1640–1648.
53. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., … Renschler, M. F. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England Journal of Medicine, 369, 1691–1703.
54. Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., … Hidalgo, M. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 4548–4554.